Central regions | Finance, business

Russia’s RVC publishes 19 exits in 2018

5 Feb '19
RVC, Russia’s national fund of funds for innovation, has unveiled its 2018 operation results. For example, last year the sovereign fund approved a total of $30.8m in investments for 30 portfolio companies, a 40% increase from its 2017 investments (which totaled $21.5m in 24 portfolio companies).

In 2018, RVC made 19 exits from their portfolio companies worth a total of $26m (from six the year before). In 18 of these, the government investor ended up in the black.

For example, in September 2018 RBV Capital, a VC fund set up jointly by RVC and R-Pharm, sold its portfolio company, botulinum toxin (BTX) developer Bonti, to Allergan, an Irish pharmaceutical giant. The Irish paid an initial amount of $195m.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Tags: RBV Capital (2) / RVC (170) / exits (0) /

Latest News: Central regions
19 Aug '19 | Finance, business | Technology & innovation
19 Aug '19 | Technology & innovation
16 Aug '19 | Finance, business | Telecoms, media
16 Aug '19 | Technology & innovation
15 Aug '19 | Finance, business | Technology & innovation

Feature stories

25 Jul '19
Russian scientists have come up with a new method of...
26 May '19
This article has been written by Carl Burch, an MBA,...
4 Apr '19
Russian scientists have come up with what they say is...
Search (News archive - 21430)
Marchmont News

Latest News

19 Aug '19
Stickeroid AI, a machine learning developer of...
16 Aug '19
MTS, one of Russia’s main mobile operators, earlier...
15 Aug '19
International investors have given the Russian Direct...

Most read stories from last week

19 Aug '19
Stickeroid AI, a machine learning developer of...